Skip to main content

Table 3 ADRs involving systematic and clinical manifestations (N = 392)

From: Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance

ADRs

Mild

Moderate

Severe

Number of patients, n (%)

Number of cases

Number of patients, n (%)

Number of cases

Number of patients, n (%)

Number of cases

Total ADRs

58 (14.8)

96

33 (8.4)

46

1 (0.3)

1

Neurological disorders

52 (13.3)

71

26 (6.6)

32

0 (0)

0

Akathisia

28 (7.1)

28

11 (2.8)

11

0 (0)

0

Tremor

17 (4.3)

18

5 (1.3)

5

0 (0)

0

Dystonia

7 (1.8)

7

5 (1.3)

6

0 (0)

0

Parkinsonism

8 (2.0)

9

4 (1.0)

4

0 (0)

0

Investigations

9 (2.3)

9

4 (1.0)

5

1 (0.3)

1

Weight gain

3 (0.8)

3

2 (0.5)

2

0(0)

0

Blood prolactin increased

2 (0.5)

2

1 (0.3)

1

1 (0.3)

1

Increased heart rate

1 (0.3)

1

1(0.3)

1

0(0)

0

elevated transaminase level

2 (0.5)

2

0 (0)

0

0 (0)

0

White blood cell count decreased

0 (0)

0

1 (0.3)

1

0 (0)

0

Blood glucose increased

1 (0.3)

1

0 (0)

0

0 (0)

0

Gastrointestinal disorders

2 (0.5)

3

2 (0.5)

2

0 (0)

0

Eye disorders

1 (0.3)

3

1 (0.3)

1

0 (0)

0

Psychiatric disorders

1 (0.3)

1

1 (0.3)

1

0 (0)

0

Kidney and urinary disorders

1 (0.3)

1

0 (0)

0

0 (0)

0

  1. ADRs = Adverse reactions